Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 10,456 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Kind Clear all
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

NCT04465877
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
JTT-662, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Not applicable Interventional Results available

Examination of Psychological Tools and Tracking in an Online Intervention for Type 2 Diabetes

NCT03037528
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
diet and lifestyle program, positive affect informational materials, mindfulness informational materials, dietary tracking
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 29, 2026, 10:17 PM EDT
Recruiting Phase 2 Interventional

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT06463665
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Phase 1 Interventional

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

NCT03725436
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm
Interventions
MDM2/MDMX Inhibitor ALRN-6924, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

NCT01412944
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 29, 2026, 10:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

NCT05626712
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions
CELZ-201 Administration, Control Group
Biological · Other
Lead sponsor
Creative Medical Technology Holdings Inc
Industry
Eligibility
18 Years to 35 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

ATG-GCSF in New Onset Type 1 Diabetes

NCT02215200
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder

NCT02066792
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Not applicable Interventional Results available

Point-of-Care Glucose Testing and Insulin Supplementation

NCT01702311
View directory record Official record
Conditions
Diabetes
Interventions
Bedtime insulin Aspart (Novolog)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 29, 2026, 10:17 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

NCT03581292
View directory record Official record
Conditions
Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions
Radiation Therapy, Temozolomide, Veliparib
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 25 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
145
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine

NCT01516892
View directory record Official record
Conditions
Migraine Disorders
Interventions
onabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
21
States / cities
Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 29, 2026, 10:17 PM EDT
Recruiting Not applicable Interventional

Mobile Health Dietary Intervention for Stroke Survivors With Prediabetes or Type 2 Diabetes

NCT07120334
View directory record Official record
Conditions
Stroke Recurrence, Type 2 Diabetes, Prediabetes
Interventions
PortionSize Ed + MedDiet Support, Standard of care for Stroke and Prediabetes or T2D
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
30 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 29, 2026, 10:17 PM EDT
Terminated Phase 1 Interventional

Islet Cell Transplants for Diabetes

NCT00303134
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplantation
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 29, 2026, 10:17 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mechanisms of Hypoglycemia Associated Autonomic Failure

NCT00678145
View directory record Official record
Conditions
Diabetes Mellitus, Hypoglycemia, Autonomic Failure
Interventions
naloxone, fructose, exercise, Morphine sulfate, Epinephrine
Drug · Dietary Supplement · Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Phase 2 Interventional

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

NCT05436639
View directory record Official record
Conditions
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
Interventions
SPI-62 dose
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 29, 2026, 10:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Electrical Impedance Myography of Neck and Low Back Pain

NCT02159677
View directory record Official record
Conditions
Low Back Pain, Neck Pain
Interventions
EIM Measurements
Device
Lead sponsor
Skulpt, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Not applicable Interventional

Behavioral Interventions to Prevent or Delay Dementia

NCT02265757
View directory record Official record
Conditions
Mild Cognitive Impairment, Memory Disorders, Mild Dementia, Impaired Cognition, Mild Cognitive Disorder, Amnestic Disorder, Dementia and Amnestic Conditions, Poor Short-term Memory, Memory Impairment
Interventions
Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group (patient and partner), Wellness Education, Physical Exercise
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus

NCT03867500
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Niacin, Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes

NCT00116207
View directory record Official record
Conditions
Diabetic Autonomic Neuropathy
Interventions
ORAL ANTIOXIDANT
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 29, 2026, 10:17 PM EDT
Withdrawn Phase 4 Interventional

Early-onset Dupilumab Effects in CRSwNP

NCT06188871
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Dupilumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Not applicable Interventional

Promoting the Use of CPAP Therapy Among OSA Patients

NCT04372329
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
CPAP4HealthySleep system
Behavioral
Lead sponsor
Sarah Alismail
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Claremont, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 29, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional

Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

NCT01597531
View directory record Official record
Conditions
Type 2 Diabetes, Gastric Banding
Interventions
Liraglutide, Orlistat, Liraglutide + Orlistat
Drug
Lead sponsor
East Carolina University
Other
Eligibility
25 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 29, 2026, 10:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19

NCT04548895
View directory record Official record
Conditions
Covid19, Community-Acquired Respiratory Tract Infection
Interventions
Observational measurement of biometric data. No change to health care provided.
Device
Lead sponsor
Health Stream Analytics, LLC
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pasco, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 29, 2026, 10:17 PM EDT
Completed Not applicable Interventional Results available

Safety and Feasibility Testing of a Smaller Network Version of AIDANET

NCT06633965
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AIDANET
Device
Lead sponsor
Marc Breton
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 29, 2026, 10:17 PM EDT